Nimenrix

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

21 competitors in Respiratory Syncytial Virus

#DrugCompanyPhaseTrials

1

Placebp

Pfizer

Phase 3

12

Mrna-1345

Moderna

Phase 1

33

Nimenrix

GSK

Phase 1

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity4 trials

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Terminated·Pfizer·Phase 2·NCT04645966·326 enrolled

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Completed·Pfizer·Phase 3·NCT04819113·149 enrolled

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Completed·GSK·Phase 3·NCT00465816·611 enrolled

Show 1 more trial

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

Completed·GSK·Phase 3·NCT01144663·2,095 enrolled

Respiratory Syncytial Virus2 trials

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Completed·Johnson & Johnson·Phase 1/2·NCT03606512·38 enrolled

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active, not recruiting·Moderna·Phase 1·NCT05743881·186 enrolled

Vaccination1 trial

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Completed·Sanofi·Phase 3·NCT01839175·350 enrolled

Vaccine1 trial

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Completed·GSK·Phase 3·NCT00514904·1,504 enrolled

Adolescent1 trial

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Completed·GSK·Phase 2·NCT00715910·818 enrolled

1 more indication

Children1 trial

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

Completed·GSK·Phase 3·NCT01266993·271 enrolled

Details

Drug Info

Related News